"Specjalizujemy się w diagnozowaniu i leczeniu bólów głowy. Stosujemy nowoczesne, zgodne ze światowymi standardami leczenia bólów głowy na świecie metody, takie jak: leczenie toksyną botulinową (botox), blokady nerwowe, zoptymalizowana farmakoterapia i wiele innych. Wzorując się na metodach stosowanych w najsłynniejszej Klinice Mayo w USA poprawiamy jakość życia pacjentów z bólami głowy. Nie jest prawdą funkcjonujący w Polsce mit, że z bólem głowy trzeba nauczyć się żyć. Korzystając ze zdobyczy światowej medycyny, jesteśmy w stanie zaoferować Państwu realną pomoc. dr. n med. Anna Gryglas-Dworak specjalista neurolog"

During the past decade, MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak" #1 collaborator was "Novartis" with 2 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak" are "Migraine" (3 trials), "Acute Treatment of Migraine" (1 trials) and "Pediatric Migraine" (1 trials). Many other conditions were trialed in "MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak" in a lesser frequency.

Most popular intervention types in "MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak" are "Drug" (5 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "Erenumab Dose 1" (2 trials), "Erenumab Dose 2" (2 trials), "Erenumab Dose 3" (2 trials) and "Erenumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak" are 5 trials for "All" genders.

Currently, there are NaN active trials in "MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak". undefined are not yet recruiting, 5 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in MIGRE Polskie Centrum Leczenia Migreny Anna Gryglas-Dworak, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".